Cancer Research Annual Meeting 2010 EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Manero, F.
Right arrow Articles by Juin, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manero, F.
Right arrow Articles by Juin, P.
[Cancer Research 66, 2757-2764, March 1, 2006]
© 2006 American Association for Cancer Research

Experimental Therapeutics, Molecular Targets, and Chemical Biology

The Small Organic Compound HA14-1 Prevents Bcl-2 Interaction with Bax to Sensitize Malignant Glioma Cells to Induction of Cell Death

Florence Manero1, Fabien Gautier1, Tristan Gallenne1, Nicolas Cauquil2, Danielle Grée3, Pierre-François Cartron1, Olivier Geneste2, René Grée3, François M. Vallette1 and Philippe Juin1

1 Institut National de la Santé et de la Reserche Médicale U601, Département de Recherche en Cancérologie, Nantes, France; 2 Cancer Research, Institut de Recherches Servier, Croissy/Seine, France; and 3 Université de Rennes 1, Synthèse et Electrosynthèse Organiques, Centre National de la Reserche Scientifique UMR 6510, Rennes, France

Requests for reprints: Philippe Juin, Institut National de la Santé et de la Reserche Médicale U601, Département de Recherche en Cancérologie, 9 Quai Moncousu, 44035 Nantes Cedex 035, France. Phone: 33-24-008-4083; Fax: 33-24-008-4082; E-mail: Philippe.Juin{at}univ-nantes.fr.

A functional imbalance between proapoptotic Bax and antiapoptotic Bcl-2 is likely to participate in the resistance of cancer cells to therapy. We show here that ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA14-1), a small organic compound recently proposed to function as an inhibitor of Bcl-2, increases the sensitivity of human glioblastoma cells to radiotherapy and chemotherapy. This sensitizing effect is lost if Bcl-2 expression, but not Bcl-xL expression, is knocked down or if cells only express a mutant of Bax that does not interact with Bcl-2. This points to a specific Bcl-2 inhibitory function of HA14-1 and implies that it selectively involves hindrance of Bcl-2 binding to Bax, which HA14-1 inhibits in cell-free assays and in cells in receipt of an apoptotic stimulation. Moreover, HA14-1, in combination with a cytotoxic treatment, slows down the growth of glioblastoma in vivo. Thus, the inhibition of Bcl-2 achieved by HA14-1 might improve treatment outcome. (Cancer Res 2006; 66(5): 2757-64)




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells
Mol. Cancer Ther., November 1, 2009; 8(11): 3162 - 3170.


Home page
 Mol. Pharmacol.Home page
D. Hermanson, S. N. Addo, A. A. Bajer, J. S. Marchant, S. G. K. Das, B. Srinivasan, F. Al-Mousa, F. Michelangeli, D. D. Thomas, T. W. LeBien, et al.
Dual Mechanisms of sHA 14-1 in Inducing Cell Death through Endoplasmic Reticulum and Mitochondria
Mol. Pharmacol., September 1, 2009; 76(3): 667 - 678.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
T. Gallenne, F. Gautier, L. Oliver, E. Hervouet, B. Noel, J. A. Hickman, O. Geneste, P.-F. Cartron, F. M. Vallette, S. Manon, et al.
Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members
J. Cell Biol., April 20, 2009; 185(2): 279 - 290.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. H. Kang and C. P. Reynolds
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Clin. Cancer Res., February 15, 2009; 15(4): 1126 - 1132.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. D. Zeitlin, I. J. Zeitlin, and J. E. Nor
Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents
J. Clin. Oncol., September 1, 2008; 26(25): 4180 - 4188.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Konopleva, J. Watt, R. Contractor, T. Tsao, D. Harris, Z. Estrov, W. Bornmann, H. Kantarjian, J. Viallet, I. Samudio, et al.
Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax)
Cancer Res., May 1, 2008; 68(9): 3413 - 3420.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. S. Ziegler, A. L. Kung, and M. W. Kieran
Anti-Apoptosis Mechanisms in Malignant Gliomas
J. Clin. Oncol., January 20, 2008; 26(3): 493 - 500.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Ren, Z. Chen, L. Chen, N. T. Woods, G. W. Reuther, J. Q. Cheng, H.-g. Wang, and J. Wu
Shp2E76K Mutant Confers Cytokine-independent Survival of TF-1 Myeloid Cells by Up-regulating Bcl-XL
J. Biol. Chem., December 14, 2007; 282(50): 36463 - 36473.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.